Sugi Predict

Sugi Predict / Targets / MTTP

MTTP

Microsomal triglyceride transfer protein large subunit · P55157 · MTTP on Sugi Atlas →

10,824 patent compounds predicted against MTTP, 4,374 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL1621570 SCHEMBL1621570 1.00 20/20
SCHEMBL1622842 SCHEMBL1622842 1.00 20/20
SCHEMBL4740096 SCHEMBL4740096 0.85 20/20
SCHEMBL3232241 SCHEMBL3232241 0.84 20/20
SCHEMBL3239404 SCHEMBL3239404 0.83 20/20
SCHEMBL690744 SCHEMBL690744 0.81 20/20
SCHEMBL4186328 SCHEMBL4186328 0.81 20/20
SCHEMBL4967763 SCHEMBL4967763 0.77 20/20
SCHEMBL4933111 SCHEMBL4933111 0.77 20/20
SCHEMBL4933118 SCHEMBL4933118 0.77 20/20
SCHEMBL4744467 SCHEMBL4744467 0.74 20/20
Hydrochloric Acid Hydrochloric Acid (SCHEMBL4785831) 0.73 20/20
Hydrochloric Acid Hydrochloric Acid (SCHEMBL4939216) 0.73 20/20
Hydrochloric Acid Hydrochloric Acid (SCHEMBL4939685) 0.72 20/20
SCHEMBL4940917 SCHEMBL4940917 0.72 20/20
SCHEMBL4784321 SCHEMBL4784321 0.70 20/20
SCHEMBL1600315 SCHEMBL1600315 0.70 20/20
SCHEMBL4939193 SCHEMBL4939193 0.69 20/20
SCHEMBL4939201 SCHEMBL4939201 0.69 20/20
SCHEMBL4984290 SCHEMBL4984290 0.68 20/20

Clinical trials — most relevant to MTTP by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
The HDL Particle Protection Study PHASE4COMPLETED
Effects of Statin and Ezetimibe Association on Kinetics of Artificial Chilomicrons PHASE4COMPLETED
The Low HDL On Six Weeks Statin Therapy (LOW) Study PHASE4UNKNOWN
Effect of Rosuvastatin Therapy on HDL2 Level PHASE4UNKNOWN
Effects of Pioglitazone on High-density Lipoprotein (HDL) Function in Persons With Diabetes PHASE3COMPLETED
Comparison of Coenzyme A and Fenofibrate for Safety and Efficacy On Patients With Hyperlipidemia PHASE3COMPLETED
The Effects of Coenzyme A Combined With Statin on Serum Lipids in Patients With Hyperlipidemia PHASE2/PHASE3UNKNOWN
A Mechanistic Study of the Effects of LY518674 on High-Density Lipoprotein Cholesterol (HDL-C) Metabolism PHASE2COMPLETED
TA-8995: Its Use in Patients With Mild Dyslipidaemia (TULIP) PHASE2COMPLETED
Effect of Gemfibrozil on Serum Glycosylphosphatidylinositol (GPI) Phospholipase D and Triglycerides PHASE1COMPLETED
Association of SGLT2 Inhibitors Therapy With Elastographic and Molecular Markers of Liver Injury in Type 2 Diabetes nanCOMPLETED
Assessment Of Lipid Profile In Cirrhotic Patients nanCOMPLETED
Effect of Saturated Fat on Large Low-density Lipoprotein (LDL) and High-density Lipoprotein (HDL) nanCOMPLETED
In Vivo Metabolism of apoB-containing Lipoproteins in ANGPTL3 Deficient Subjects nanUNKNOWN
Development of Biomarker for Development of Non-Alcoholic Steatohepatitis (NASH) in Children nanWITHDRAWN
Genetic Epidemiology of Lipoprotein-Lipid Levels nanCOMPLETED
Evaluation of HDL Subfraction Changes and HDL-Associated Enzymes in Liver Failure Patients and Healthy Donors nanCOMPLETED
The Association of SAA With Apolipoprotein B Affects Cardiovascular Risk nanCOMPLETED
Canagliflozin on Liver Inflammation Damage in Type 2 Diabetes Patients With Nonalcoholic Fatty Liver Disease nanUNKNOWN
Epidemiology of Atherosclerosis nanCOMPLETED
Effect of Omega-3 Fatty Acids Supplementation on Hypertriglyceridemia in Pediatric Patients With Obesity. nanCOMPLETED
Pharmacogenetics of Hypertriglyceridemia in Hispanics nanCOMPLETED
Association Between HDL Functions and Atherosclerotic Burden in Healthy Individuals nanCOMPLETED
Fish Oil and Nonalcoholic Fatty Liver Disease (NAFLD) Study nanCOMPLETED
Genetic and Environmental Determinants of Triglycerides (GOLDN) nanCOMPLETED
Risk Burden of Lipoprotein Metabolic Gene Haplotypes nanCOMPLETED
A Registration Study for Familial Hypercholesterolemia in Taiwan nanUNKNOWN
Triglyceride-rich LIPoproteins and INflammatory Cytokines After Oral FAT Loading as Potential Early Biomarkers of the Risk of Progression Towards DIABETES and Development of Complications. LIPINFAT Diabetes Study. nanRECRUITING
The Effect Of DAAs on miRNA-122 And Insulin Resistance In Chronic HCV Patients nanUNKNOWN
Plasma Triglyceride Lipolysis in Multifactorial Chylomicronemia nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a MTTP binder may also engage these)

ProteinNameSimilarity
P55156 — 1.000 P55156 →
Q865F1 — 1.000 Q865F1 →
D4A1W8 — 1.000 D4A1W8 →
P55158 — 1.000 P55158 →
A0A0R4IVV0 — 1.000 A0A0R4IVV0 →
O08601 — 1.000 O08601 →
A0A0N6WHT4 — 0.999 A0A0N6WHT4 →
Q7TMA5 — 0.994 Q7TMA5 →
APOB Apolipoprotein B-100 0.992 landscape →
E9Q414 — 0.990 E9Q414 →
Q98893 — 0.987 Q98893 →
Q90243 — 0.986 Q90243 →
Q7Z1M0 — 0.985 Q7Z1M0 →
P02845 — 0.984 P02845 →
Q868N5 — 0.982 Q868N5 →
P87498 — 0.980 P87498 →
Q05808 — 0.980 Q05808 →
Q90508 — 0.980 Q90508 →
P18709 — 0.980 P18709 →
Q92093 — 0.979 Q92093 →
Q91062 — 0.978 Q91062 →
Q2VQM6 — 0.977 Q2VQM6 →
P18948 — 0.977 P18948 →
Q9U943 — 0.977 Q9U943 →
Q9N4J2 — 0.977 Q9N4J2 →
P55155 — 0.977 P55155 →
P06125 — 0.977 P06125 →
Q6DDG2 — 0.976 Q6DDG2 →
Q9DBG6 — 0.976 Q9DBG6 →
Q9NYU1 — 0.975 Q9NYU1 →